Conclusions
bleeding
BLEEDING
In this randomized clinical trial evaluating the use of a real-time, prognostic model to reduce rates of HA-VTE in hospitalized children and adolescents, the automated, EMR-integrated model functioned well to estimate risk of pediatric inpatients developing HA-VTE and did not demonstrate an increased risk of bleeding, but overall acceptance of the recommendations from the hematology research team was low and use of the model in this context did not improve patient outcomes. Moving forward, we are considering additional ways to assess the success of future studies, including the use of quality improvement metrics such as aim statements, plan-do-study-act cycles, and run charts, in addition to more traditional research mechanisms to identify the best strategies to prevent pediatric HA-VTEs. Overall, we anticipate optimizing anticoagulation dosing and overcoming barriers to implementation and adoption of the HA-VTE model in clinical practice to be the most important next steps.